Until recently, injection was considered to be the most efficient form of BPC-157 administration
The guideline states: "For children ages 12 years and older with obesity, pediatricians and other primary care providers should offer weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment" [8]
[2,3,4] In the best withdrawal evidence available, stopping tirzepatide led to substantial regain, while continuing it maintained and augmented weight loss
44, 77 Methymalonic acid, a metabolite of PPA, results in abnormal mitochondrial morphology, 78 tissue specific ETC dysfunction, 79 inhibition of the complex I and II function when interacting with complex III in the brain 80 and reductions in reduced glutathione, 78 similar to the patient cohort presented and the PPA animal model